Penserra Capital Management’s TriSalus Life Sciences TLSI Stock Holding History

Penserra Capital Management’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,706	Closed	-$26K	–	1208
2022 Q2	$26K	Sell	2,706 -462	-15%	-$4.54K	﹤0.01%	1061
2022 Q1	$31K	Sell	3,168 -2,325	-42%	-$22.9K	﹤0.01%	1126
2021 Q4	$54K	Buy	+5,493	New	+$54.6K	﹤0.01%	1006

Other funds holding TLSI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

RPO LLC Stamford, Connecticut $32.3M AUM 14.17% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Penserra Capital Management's TLSI Position: Q3 2022 in Review

Penserra Capital Management sold out of TriSalus Life Sciences (TLSI) in Q3 2022, closing a stake of 2,706 shares — an estimated $26K sold.

Penserra Capital Management first reported a position in TLSI in Q4 2021 and held it in 3 quarters. The position peaked at $54K in Q4 2021. 72 funds tracked by Wall St. Rank hold TLSI as of Q3 2022.

Penserra Capital Management reported no remaining TriSalus Life Sciences position as of Q3 2022 after selling out during the quarter.
Penserra Capital Management sold 2,706 TriSalus Life Sciences shares in Q3 2022, an estimated $26K.
Penserra Capital Management first reported a position in TriSalus Life Sciences in Q4 2021 and held it in 3 quarters.
Penserra Capital Management's TriSalus Life Sciences position peaked at $54K in Q4 2021.
72 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.